Clinical Report: Does Lithium Improve Agitation After Valproate in Schizophrenia?

Overview

This case report suggests that lithium augmentation may reduce agitation and aggression in a patient with treatment-resistant schizophrenia after discontinuation of valproate due to adverse effects. Clinical outcomes indicated significant improvements in behavioral symptoms following lithium treatment, but findings are based on a single case study.

Background

Agitation and aggression are common challenges in managing schizophrenia, particularly in treatment-resistant cases. The use of mood stabilizers like lithium as adjunctive therapy may offer a potential strategy for improving patient outcomes. Understanding the efficacy and safety of such treatments is crucial for optimizing care in this population, especially given the complexities of treatment-resistant schizophrenia.

Data Highlights

Key Findings

• Lithium augmentation was initiated after valproate was discontinued due to hypoglycemia and pancytopenia.
• Agitation and dangerous behaviors decreased after achieving a serum lithium level of 0.8 mEq/L.
• The BPRS total score improved significantly from 80 to 64.
• No psychiatric readmission occurred during the 3-month follow-up period.
• Improvements were primarily noted in behavioral symptoms rather than core psychotic features.
• Limitations include the single-case design and potential confounding factors such as antipsychotic dose changes and the natural course of illness.

Clinical Implications

Clinicians may consider lithium as a potential augmentation strategy for managing agitation in patients with treatment-resistant schizophrenia, particularly after adverse reactions to other medications. However, ongoing monitoring of lithium levels and patient symptoms is essential to optimize treatment outcomes, and further research is needed to validate these findings.

Conclusion

This case highlights the potential benefits of lithium augmentation in reducing agitation in treatment-resistant schizophrenia, although further research is needed to establish causality and generalizability. Caution is advised in interpreting these results due to the study's limitations.

References

1. Kasagi Y, et al., PCN Reports, 2023 -- Does Lithium Improve Agitation After Valproate in Schizophrenia?
2. BMC Psychiatry, 2023 -- Pharmacological management of acute agitation in psychiatric patients: an umbrella review
3. MIRECC, 2025 -- Pharmacological and Somatic Treatments for First-Episode Psychosis and Schizophrenia: Synopsis of VA/DoD CPG
4. BMC Psychiatry (Springer) — Examining valproate’s potential anticancer effect among patients with bipolar disorder: a territory-wide active-comparator new user study spanning two decades
5. Drug Safety — Cardiovascular Assessment of Valbenazine: A Comprehensive Review of Data from Three Randomized, Double-Blind, Placebo-Controlled Studies
6. Drugs - Real World Outcomes — Evaluating the Association of Lithium Carbonate with Clozapine Side Effects, Including Neutropenia: Insights from the Japanese Adverse Drug Event Report Database
7. Hypercalcemia Linked to Lithium: Mechanisms, Frequency, and Treatment Approaches
8. Examining valproate’s potential anticancer effect among patients with bipolar disorder
9. Cardiovascular Assessment of Valbenazine
10. Evaluating the Association of Lithium Carbonate with Clozapine Side Effects
11. “Pharmacological management of acute agitation in psychiatric patients: an umbrella review” | BMC Psychiatry | Full Text
12. Pharmacological and Somatic Treatments for First-Episode Psychosis and Schizophrenia: Synopsis of the US Department of Veterans Affairs and US Department of Defense Clinical Practice Guidelines
13. Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: consensus guidelines from a global Delphi panel - ScienceDirect
14. Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis Study - PubMed